Optical coherence tomography measurements as potential imaging biomarkers for Parkinson's disease: A systematic review and meta-analysis
Wen-Chuan Zhou
Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China
Search for more papers by this authorJin-Xin Tao
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Search for more papers by this authorCorresponding Author
Jing Li
Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China
Correspondence
Jing Li, Department of Ophthalmology, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, No. 1665, Kongjiang Road, Shanghai 200092, China.
Email: [email protected]
Search for more papers by this authorWen-Chuan Zhou
Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China
Search for more papers by this authorJin-Xin Tao
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Search for more papers by this authorCorresponding Author
Jing Li
Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China
Correspondence
Jing Li, Department of Ophthalmology, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, No. 1665, Kongjiang Road, Shanghai 200092, China.
Email: [email protected]
Search for more papers by this authorAbstract
Background and purpose
Retinal pathological changes may precede or accompany the deterioration of brain tissue in Parkinson's disease (PD). The purpose of this meta-analysis was to assess the usefulness of optical coherence tomography (OCT) measurements as potential imaging biomarkers for PD.
Methods
PubMed, Embase, Web of Science and Cochrane Library databases were systematically searched for observational studies (published prior to 30 May 2020) comparing the OCT measurements between PD patients and healthy controls (HCs). Our main end-points were peripapillary retinal nerve fiber layer (pRNFL) thickness, macular ganglion cell complex thickness, macular thickness and macular volume. Pooled data were assessed by use of a random-effects model.
Results
A total of 36 observational studies were identified that included 1712 patients with PD (2548 eyes) and 1778 HCs (2646 eyes). Compared with the HC group, the PD group showed a significant reduction in mean pRNFL thickness (weighted mean difference [WMD] −3.51 μm, 95% confidence interval [CI] −4.84, −2.18; p = 0.000), all quadrants at the pRNFL (WMD range −7.65 to −2.44 μm, all p < 0.05), macular fovea thickness (WMD −5.62 μm, 95% CI −7.37, −3.87; p = 0.000), all outer sector thicknesses at the macula (WMD range −4.68 to −4.10 μm, all p < 0.05), macular volume (WMD −0.21 mm3, 95% CI −0.36, −0.06; p < 0.05) and macular ganglion cell complex thickness (WMD −4.18 μm, 95% CI −6.07, −2.29; p < 0.05).
Conclusions
Our pooled data confirmed robust associations between retinal OCT measurements and PD, highlighting the usefulness of OCT measurements as potential imaging biomarkers for PD.
CONFLICT OF INTEREST
There is no conflict of interest related to the submitted paper.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Supporting Information
| Filename | Description |
|---|---|
| ene14613-sup-0001-AppS1.docxWord document, 19.7 MB |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Beitz JM. Parkinson's disease: a review. Front Biosci (Schol Ed). 2014; 6: 65-74.
- 2Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord. 2001; 16: 507-510.
- 3Bodis-Wollner I. Retinopathy in Parkinson disease. J Neural Transm (Vienna). 2009; 116: 1493-1501.
- 4Mohana Devi S, Mahalaxmi I, Aswathy NP, Dhivya V, Balachandar V. Does retina play a role in Parkinson's disease? Acta Neurol Belg. 2020; 120: 257-265.
- 5Akopian A, Witkovsky P. D2 dopamine receptor-mediated inhibition of a hyperpolarization-activated current in rod photoreceptors. J Neurophysiol. 1996; 76: 1828-1835.
- 6Chaudhuri KR, Sauerbier A. Parkinson disease. Unravelling the nonmotor mysteries of Parkinson disease. Nat Rev Neurol. 2016; 12: 10-11.
- 7Djamgoz MB, Hankins MW, Hirano J, Archer SN. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res. 1997; 37: 3509-3529.
- 8Muresan Z, Besharse JC. D2-like dopamine receptors in amphibian retina: localization with fluorescent ligands. J Comp Neurol. 1993; 331: 149-160.
- 9Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Trends Neurosci. 1990; 13: 296-302.
- 10Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology. 1992; 42: 887-890.
- 11Kaur M, Saxena R, Singh D, Behari M, Sharma P, Menon V. Correlation between structural and functional retinal changes in Parkinson disease. J Neuroophthalmol. 2015; 35: 254-258.
- 12Ong SS, Proia AD, Whitson HE, Farsiu S, Doraiswamy PM, Lad EM. Ocular amyloid imaging at the crossroad of Alzheimer's disease and age-related macular degeneration: implications for diagnosis and therapy. J Neurol. 2018; 266: 1566-1577.
- 13Gaenslen A, Berg D. Early diagnosis of Parkinson's disease. Int Rev Neurobiol. 2010; 90: 81-92.
- 14Südmeyer M, Antke C, Zizek T, et al. Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: a multidimensional statistical approach. J Nucl Med. 2011; 52: 733-740.
- 15Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clinical Research Ed). 2015; 350: g7647.
- 16Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283: 2008-2012.
- 17Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25: 603-605.
- 18Wells G, Shea B, O'Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis; 2007. http://www ohri ca/programs/clinical epidemiology/oxford html
- 19Albrecht P, Müller AK, Südmeyer M, et al. Optical coherence tomography in parkinsonian syndromes. PLoS One. 2012; 7:e34891.
- 20Alkabie S, Lange A, Manogaran P, Stoessl AJ, Costello F, Barton JJS. Optical coherence tomography of patients with Parkinson's disease and progressive supranuclear palsy. Clin Neurol Neurosurg. 2020; 189:105635.
- 21Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Retinal thickness in Parkinson's disease. Parkinsonism Relat Disord. 2011; 17: 431-436.
- 22Aydin TS, Umit D, Nur OM, et al. Optical coherence tomography findings in Parkinson's disease. Kaohsiung J Med Sci. 2018; 34: 166-171.
- 23Bayhan HA, Aslan Bayhan S, Tanık N, Gürdal C. The association of spectral-domain optical coherence tomography determined ganglion cell complex parameters and disease severity in Parkinson's disease. Curr Eye Res. 2014; 39: 1117-1122.
- 24Bittersohl D, Stemplewitz B, Keserü M, Buhmann C, Richard G, Hassenstein A. Detection of retinal changes in idiopathic Parkinson's disease using high-resolution optical coherence tomography and Heidelberg retina tomography. Acta Ophthalmol. 2015; 93: e578-e584.
- 25Eraslan M, Cerman E, Yildiz Balci S, et al. The choroid and lamina cribrosa is affected in patients with Parkinson's disease: enhanced depth imaging optical coherence tomography study. Acta Ophthalmol. 2016; 94: e68-e75.
- 26Garcia-Martin E, Larrosa JM, Polo V, et al. Distribution of retinal layer atrophy in patients with Parkinson disease and association with disease severity and duration. Am J Ophthalmol 2014; 157: 470–478.e2.
- 27Garcia-Martin E, Rodriguez-Mena D, Satue M, et al. Electrophysiology and optical coherence tomography to evaluate Parkinson disease severity. Invest Ophthalmol Vis Sci. 2014; 55: 696-705.
- 28Gulmez Sevim D, Unlu M, Sonmez S, Gultekin M, Karaca C, Ozturk Oner A. Retinal vessel diameter obtained by optical coherence tomography is spared in Parkinson's disease. Int Ophthalmol. 2018; 39: 813-819.
- 29Huang J, Li Y, Xiao J, et al. Combination of multifocal electroretinogram and spectral-domain OCT can increase diagnostic efficacy of Parkinson's disease. Parkinson's Dis. 2018; 2018:4163239.
- 30Jiménez B, Ascaso FJ, Cristóbal JA, López del Val J. Development of a prediction formula of Parkinson disease severity by optical coherence tomography. Mov Disord. 2014; 29: 68-74.
- 31Kirbas S, Turkyilmaz K, Tufekci A, Durmus M. Retinal nerve fiber layer thickness in Parkinson disease. J Neuroophthalmol. 2013; 33: 62-65.
- 32Lee JY, Kim JM, Ahn J, Kim HJ, Jeon BS, Kim TW. Retinal nerve fiber layer thickness and visual hallucinations in Parkinson's disease. Mov Disord. 2014; 29: 61-67.
- 33Ma LJ, Xu LL, Mao CJ, et al. Progressive changes in the retinal structure of patients with Parkinson's disease. J Parkinson's Dis. 2018; 8: 85-92.
- 34Mailankody P, Battu R, Khanna A, Lenka A, Yadav R, Pal PK. Optical coherence tomography as a tool to evaluate retinal changes in Parkinson's disease. Parkinsonism Relat Disord. 2015; 21: 1164-1169.
- 35Matlach J, Wagner M, Malzahn U, et al. Retinal changes in Parkinson's disease and glaucoma. Parkinsonism Relat Disord. 2018; 56: 41-46.
- 36Moschos MM, Chatziralli IP. Evaluation of choroidal and retinal thickness changes in Parkinson's disease using spectral domain optical coherence tomography. Semin Ophthalmol. 2018; 33: 494-497.
- 37Pilat A, McLean RJ, Proudlock FA, et al. In vivo morphology of the optic nerve and retina in patients with Parkinson's disease. Invest Ophthalmol Vis Sci. 2016; 57: 4420-4427.
- 38Pillai JA, Bermel R, Bonner-Jackson A, et al. Retinal nerve fiber layer thinning in Alzheimer's disease: a case–control study in comparison to normal aging, Parkinson's disease, and non-Alzheimer's dementia. Am J Alzheimer's Dis Other Demen. 2016; 31: 430-436.
- 39Polo V, Satue M, Rodrigo MJ, et al. Visual dysfunction and its correlation with retinal changes in patients with Parkinson's disease: an observational cross-sectional study. BMJ Open. 2016; 6:e009658.
- 40Quagliato LB, Domingues C, Quagliato EMAB, Abreu EBd, Kara-Junior N. Applications of visual evoked potentials and Fourier-domain optical coherence tomography in Parkinson's disease: a controlled study. Arq Bras Oftalmol. 2014; 77: 238-242.
- 41Roth NM, Saidha S, Zimmermann H, et al. Photoreceptor layer thinning in idiopathic Parkinson's disease. Mov Disord. 2014; 29: 1163-1170.
- 42Sari ES, Koc R, Yazici A, Sahin G, Ermis SS. Ganglion cell-inner plexiform layer thickness in patients with Parkinson disease and association with disease severity and duration. J Neuroophthalmol. 2015; 35: 117-121.
- 43Satue M, Garcia-Martin E, Fuertes I, et al. Use of Fourier-domain OCT to detect retinal nerve fiber layer degeneration in Parkinson's disease patients. Eye (Lond). 2013; 27: 507-514.
- 44Satue M, Obis J, Alarcia R, et al. Retinal and choroidal changes in patients with Parkinson's disease detected by swept-source optical coherence tomography. Curr Eye Res. 2018; 43: 109-115.
- 45Satue M, Rodrigo MJ, Obis J, et al. Evaluation of progressive visual dysfunction and retinal degeneration in patients with Parkinson's disease. Invest Ophthalmol Vis Sci. 2017; 58: 1151-1157.
- 46Satue M, Seral M, Otin S, et al. Retinal thinning and correlation with functional disability in patients with Parkinson's disease. Br J Ophthalmol. 2014; 98: 350-355.
- 47Sen A, Tugcu B, Coskun C, Ekinci C, Nacaroglu SA. Effects of levodopa on retina in Parkinson disease. Eur J Ophthalmol. 2014; 24: 114-119.
- 48Stemplewitz B, Keserü M, Bittersohl D, et al. Scanning laser polarimetry and spectral domain optical coherence tomography for the detection of retinal changes in Parkinson's disease. Acta Ophthalmol. 2015; 93: e672-e677.
- 49Tsironi EE, Dastiridou A, Katsanos A, et al. Perimetric and retinal nerve fiber layer findings in patients with Parkinson's disease. BMC Ophthalmol. 2012; 12: 54.
- 50Tugcu B, Melikov A, Yildiz GB, et al. Evaluation of retinal alterations in Parkinson disease and tremor diseases. Acta Neurol Belg. 2020; 120: 107-113.
- 51Ucak T, Alagoz A, Cakir B, Celik E, Bozkurt E, Alagoz G. Analysis of the retinal nerve fiber and ganglion cell-inner plexiform layer by optical coherence tomography in Parkinson's patients. Parkinsonism Relat Disord. 2016; 31: 59-64.
- 52Unlu M, Gulmez Sevim D, Gultekin M, Karaca C. Correlations among multifocal electroretinography and optical coherence tomography findings in patients with Parkinson's disease. Neurol Sci. 2018; 39: 533-541.
- 53Visser F, Vermeer KA, Ghafaryasl B, et al. In vivo exploration of retinal nerve fiber layer morphology in Parkinson's disease patients. J Neural Transm (Vienna). 2018; 125: 931-936.
- 54Yu DY, Cringle SJ, Balaratnasingam C, Morgan WH, Yu PK, Su EN. Retinal ganglion cells: energetics, compartmentation, axonal transport, cytoskeletons and vulnerability. Prog Retin Eye Res. 2013; 36: 217-246.
- 55Djamgoz MB, Wagner HJ. Localization and function of dopamine in the adult vertebrate retina. Neurochem Int. 1992; 20: 139-191.
- 56Frederick JM, Rayborn ME, Laties AM, Lam DM, Hollyfield JG. Dopaminergic neurons in the human retina. J Comp Neurol. 1982; 210: 65-79.
- 57Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophthalmol Vis Sci. 1990; 31: 2473-2475.
- 58Chan VTT, Sun Z, Tang S, et al. Spectral-domain OCT measurements in Alzheimer's disease: a systematic review and meta-analysis. Ophthalmology. 2019; 126: 497-510.
- 59Mendoza-Santiesteban CE, Gabilondo I, Palma JA, Norcliffe-Kaufmann L, Kaufmann H. The retina in multiple system atrophy: systematic review and meta-analysis. Front Neurol. 2017; 8: 206.
- 60Goetz CG, Stebbins GT, Ouyang B. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov Disord. 2011; 26: 2196-2200.
- 61Lee J-Y, Ahn J, Kim TW, Jeon BS. Optical coherence tomography in Parkinson's disease: is the retina a biomarker? J Parkinson's Dis. 2014; 4: 197-204.
- 62Liu Y, Guo W, Zhang J, et al. Urinary interleukin 18 for detection of acute kidney injury: a meta-analysis. Am J Kidney Dis. 2013; 62: 1058-1067.
- 63Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928.
